Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SJALL23H: Combination Antigen-Directed Induction Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

NCT06533748 is registered in ClinicalTrials.gov with St. Jude Children's Research Hospital as lead sponsor.

NCT NCT06533748
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06533748 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SJALL23H: Combination Antigen-Directed Induction Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
Lead sponsor
St. Jude Children's Research Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
January 23, 2025
Completion date
May 31, 2034
Enrollment
128 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia, lymphoblastic lymphoma